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Abstract: Productive replication of DNA viruses elicits
host cell DNA damage responses, which cause both
beneficial and detrimental effects on viral replication. In
response to the viral productive replication, host cells
attempt to attenuate the S-phase cyclin-dependent kinase
(CDK) activities to inhibit viral replication. However,
accumulating evidence regarding interactions between
viral factors and cellular signaling molecules indicate that
viruses utilize them and selectively block the downstream
signaling pathways that lead to attenuation of the high S-
phase CDK activities required for viral replication. In this
review, we describe the sophisticated strategy of Epstein-
Barr virus to cancel such ‘‘noisy’’ host defense signals in
order to hijack the cellular environment.
Introduction
Cellular DNA damage responses initiate with activation and
rapid recruitment of repair proteins to DNA damage sites [1,2].
Until the damage is repaired, cells are prevented from transition-
ing to the next stage of the cell cycle. The tumor suppressor p53 is
phosphorylated by DNA damage–responsive kinases, resulting in
stabilization of p53 and an increase in its protein level. This leads
to activation of target gene transcription including p53 itself,
which subsequently causes cell cycle arrest or apoptosis [3,4]. The
replicated viral genomes of DNA viruses, including adenoviruses,
the polyomavirus, and herpesviruses, are recognized by cellular
DNA damage sensors, triggering activation of DNA damage
responses [5,6,7,8,9]. Several lines of evidence revealed viral
approaches to create an optimal environment for viral replication
by manipulating the host defense systems. In this review, we
describe the elegant strategies used by Epstein-Barr virus (EBV) to
cancel ‘‘noisy’’ cellular signaling in order to manipulate the
cellular environment for its own genome replication.
Life Cycle of the Epstein-Barr Virus
EBV, a human lymphotropic herpesvirus, infects more than
90% of world’s population and is now known to contribute to a
variety of human disorders, including infectious mononucleosis,
nasopharyngeal carcinoma, Burkitt’s lymphoma, and lymphopro-
liferative diseases occurring in immune-compromised individuals
[10]. The lifecycle of EBV is quite distinctive, featuring two
alternative infection cycles: ‘‘latent’’ and ‘‘lytic.’’ Primary EBV
infection targets resting B lymphocytes, inducing their continuous
proliferation. In the resultant B lymphoblastoid cell lines that
express a limited number of EBV gene products, the viral genomes
are maintained as circular plasmids forming nucleosomal
structures with histones [11], and there is no production of virus
particles, this being called ‘‘latent’’ infection. In the latent state,
viral DNA is replicated only once during S phase, just as host
chromosomal DNA [11]. Only a small percentage of infected cells
switch their states from the latent stage into the ‘‘lytic’’ cycle to
produce progeny viruses. EBV DNA replication occurs at discrete
sites in nuclei called ‘‘replication compartments,’’ where all of the
viral replication proteins are assembled [12]. During lytic
replication, the circular genome becomes a ready template for
amplification by the viral replication machinery, generating
thousands of copies per cell. This reactivation is correlated with
the emergence of human cancers [13,14]. The switch from latent
to lytic replication is triggered by expression of the EBV BZLF1
gene product (also called Zta or ZEBRA) [15]. The BZLF1 protein
is a lytic replication origin binding protein and acts to transactivate
various viral promoters [16], leading to an ordered cascade of viral
gene expression: activation of early genes followed by viral genome
replication and late gene expression. Using the EBV system, the
alteration in cellular conditions, from latent to virus-productive
infection without overlapping signals triggered by virus entry, can
be monitored [17,18].
Regulation of p53 during the Latent Phase of EBV
Infection
In uninfected cells, p53 is hypophosphorylated [9] and its level
is regulated by cellular E3 ubiquitin ligase MDM2 and cellular
ubiquitin–specific protease USP7 (Figure 1A) [19]. The EBV
latent protein, EBNA1, contributes to repression of p53-dependent
DNA damage signaling by competition of the USP7 binding site
with p53 (Figure 1A) [20] (Figure 1A). Furthermore, this
interaction between EBNA1 and USP7 leads to the disruption of
PML bodies, the nuclear structures important for p53 activation
and DNA repair [21]. These findings suggest that EBNA1
expression protects cells from DNA damage–induced apoptosis
by destabilizing p53 protein. This possible mechanism points to an
important role of EBNA1 in cancer development by allowing
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latent EBV-infected cells.
The Important Role of p53 in the Early Stages of
EBV Lytic Replication
We propose that, during the course of lytic replication, BZLF1
protein plays two distinct roles in the regulation of p53-mediated
transactivation, which depend on the progression of lytic
replication: the early stage and the middle to late stages (described
below) (Figure 1B). Previous studies demonstrated that the EBV
immediate-early protein BZLF1, which was either conditionally
expressed [22,23] or overexpressed by a recombinant adenovirus
[24,25], could induce G1 arrest in some cell lines. The BZLF1
protein causes the accumulation of both mRNA and protein of
CDK inhibitor p21
Cip1/Waf1 [23], a well-known p53-target gene
product. BZLF1 protein accelerates the rate of p53-DNA complex
formation through physical interaction with p53 [26]. In the early
phases of lytic replication, p53 is hypophosphorylated and
therefore exhibits weak DNA binding ability to its recognition
sequences [9]. The BZLF1 protein helps the hypophosphorylated
p53 to bind to its recognition sequences, leading to the
enhancement of p53-dependent transcription [26]. Levels of p53
and p21
Cip1/Waf1 are transiently elevated in the early stages of lytic
replication, and then decline with the progression of lytic infection
[26], probably reflecting the effects of BZLF1 expression.
Recently, we and other groups have shown that p53 is involved
in reactivation of EBV [26,27]. Tsai and his colleagues have
reported that induction of viral lytic proteins by a chemical
inducer, sodium butylate, does not occur in p53-negative H1299A
and Saos2A cells [27], although the ability of BZLF1 or BRLF1
protein to transactivate its downstream genes is not notably
affected by the lack of p53 [28,29]. This implies that p53 might
instead be required for a switch from the latent to the lytic cycle.
Indeed, we found that overexpression of p53 in the early stages of
lytic replication enhances subsequent viral genome replication
[26].
In the case of human cytomegalovirus (HCMV), the level of p53
is elevated upon viral infection, but its downstream transcriptional
targets remain inactivated [30,31]. It has been reported that cells
infected with HCMV in the absence of p53 produce fewer
infectious viral particles and cause delays in viral protein
production and trafficking [30]. The HCMV genome has 21
potential p53-responsive sites [32]. HCMV gene expression is
thought to be influenced by p53 molecules bound to HCMV
genome at immediate-early and early stages of the infection, which
Figure 1. Stage-specific regulation of p53 during EBV infection. (A) The ubiquitination of p53 is regulated by both MDM2 E3 ligase and USP7
deubiquitinase in uninfected cells. During EBV latent infection, EBV latent EBNA1 protein inhibits USP7 and thereby drives the ubiquitination of p53.
Phosphorylated p53 is ubiquitinated by BZLF1 protein-associated E3 ligase independently of MDM2 during lytic infection. (B) During the latent phase
of EBV infection, p53 is quantitatively regulated by MDM2 ubiquitin ligase via the ubiquitin-proteasome pathway [36], serving as a guardian of
genome stability. Expression of BZLF1 protein induces virus-productive (lytic) replication through the ordered cascades of viral gene expression, and
concomitantly host DNA damage responses [9], leading to p53 phosphorylation and release of p53 from the MDM2-dependent regulation [36]. In the
early stages of lytic infection, the inactive (hypophosphorylated) form of p53 cooperates with viral factors including BZLF1 protein to stimulate virus
replication [26,27]. In the middle and late stages of infection, active (hyperphosphorylated) p53 is ubiquitinated by BZLF1 protein–associated ECS
ubiquitin ligase complexes and is degraded in a proteasome-dependent manner to inhibit apoptosis [37].
doi:10.1371/journal.ppat.1001158.g001
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of virions in p53-negative cells. Similarly, potential p53 recogni-
tion sequences are present on the EBV genome (T. Murata et al.,
unpublished results). Indeed, we have found that p53 is associated
with EBV replication compartments [9]. Thus, in the early stages
of EBV lytic infection, p53 could be recruited to the EBV genomic
regions through its direct binding to the recognition sequences.
The BZLF1-mediated enhancement of p53-DNA binding may
therefore contribute to the expression of viral genes (Figure 1B).
Newly Synthesized Viral DNA Elicits Host DNA
Damage Responses
Herpesviruses such as HSV, HCMV, and EBV modulate the
cell cycle to promote a transition through G1-S phase and achieve
the cellular environment with high S-phase CDK activities, called
the S-phase-like condition, for virus-productive replication (re-
viewed in [18]). During the EBV lytic replication, the levels of
cyclin E and cyclin A continue to be elevated, and cyclin E- and
cyclin A-associated CDK activities actually increase [9]. More-
over, this elevation of S-phase CDK activities drives accumulation
of the hyperphosphorylated form of retinoblastoma protein (Rb)
and an increase in the level of E2F-1 transcription factor [9]. The
observation that chemical CDK inhibitors, such as purvalanol A
and roscovitine, block viral lytic replication through prevention of
viral immediate-early and early gene expression [33] suggests that
a cellular environment featuring high CDK activities is required
for efficient viral replication. It is conceivable that expression of
proteins involved in DNA metabolism may be promoted under S-
phase conditions, when energy generation and other resources
support viral replication [18]. However, cellular DNA synthesis is
almost entirely blocked during the lytic phase of EBV DNA
replication, despite S-phase-like cellular conditions with high CDK
activities [17]. The EBV-encoding protein kinase (PK) BGLF4
phosphorylates MCM complex to inhibit its replicative helicase
activity (Figure 2) [34]. Although the precise mechanism remains
unclear, it might be one of the reasons for inhibition of
chromosomal DNA replication and for the blockage of the cell-
cycle progression from S to G2 phase.
The host cell DNA damage-sensing machinery recognizes the
newly synthesized viral DNA in the lytic phase as ‘‘abnormal’’
DNA, activating ATM-dependent DNA damage signaling [9]
(Figure 2). ATM phosphorylates histone H2AX (H2AX), which
initiates the DNA damage response. The EBV BGLF4 PK might
further amplify this response through phosphorylation of H2AX
[35]. ATM phosphorylates p53 at Ser-15, which liberates p53
from MDM2-mediated degradation. The downstream kinases of
ATM, Chk1, and Chk2 also phosphorylate p53 at various sites.
Therefore, elicitation of DNA damage responses in general
activates the transcriptional functions of p53.
Ubiquitin-Mediated Degradation of p53 in the
Middle and Late Stages of Lytic Infection
Paradoxically, reactivation of EBV induces cellular DNA
damage responses that causes phosphorylation of p53, which
could lead to accumulation of p53 and subsequent activation of
p53 downstream signaling (Figure 1), at the same time it
establishes the S-phase-like cellular environment. At the middle
to late stages of the lytic replication, the p53 target gene products
are indeed maintained at low levels [9,17,26,36]. An explanation
for this comes from the observation that p53 is degraded via the
ubiquitin-proteasome pathway in the middle and late stages of
lytic infection, allowing EBV to exploit cellular environments with
high CDK activities for efficient viral replication (Figure 2).
A series of recent studies have shown that induction of the EBV
lytic program leads to degradation of p53 via a ubiquitin-
proteasome pathway independently of MDM2 [36]. The BZLF1
protein functions as an adaptor component of the ECS (Elongin
B/C-Cul2/5-SOCS-box protein) ubiquitin ligase complex that
targets both unphosphorylated and hyperphosphorylated p53 for
degradation (Figure 2) [37]. The BZLF1 M3 mutant, which lacks
the ability to bind to Cullin 2 and 5, degrades p53 very little in
EBV-positive cells, and the yield of infectious viruses is poorer than
in wild-type BZLF1-expressing cells [37]. The BZLF1 M3 mutant
includes a mutation at residue E54, previously reported to prevent
activation of the EBV lytic cycle, but the underlying mechanism
was unknown [38]. These findings suggest that the deficiency of
viral replication is due to the failure of p53 degradation.
Chk2 is known to mediate phosphorylation of p53 at Ser-366
and Ser-378 in response to genotoxic stresses [39]. Indeed, p53 is
phosphorylated at least at Ser-15, Ser-20, Ser-366, and Ser-378
with progression of EBV lytic infection [37]. Intriguingly, C-
terminal phosphorylation of p53 at both Ser-366 and Ser-378
enhances the association with BZLF1 protein and subsequent
ubiquitination of p53 [37], possibly through the phosphorylation-
induced conformational change of p53. These results suggest that
DNA damage responses play a pivotal role in lytic infection.
In addition, inhibition of p53 degradation by the BZLF1 M3
mutant induces apoptotic cellular changes [37]. The maintenance
of p53 at very low levels, therefore, is required not only for
establishing S-phase-like conditions [9,17,36], but also for
inhibiting apoptosis for efficient viral propagation. In fact, caspase
activity is not induced during lytic infection [40]. Similarly, a body
of evidence in the herpesvirus family shows that p53 is inactivated
in lytic replication, although its molecular mechanism is
controversial [41,42,43].
Thus, studies on the relationship between p53 alteration and
viral DNA replication have demonstrated that BZLF1 enables
hypophosphorylated p53 to transactivate the p53 target genes in
the initial phase of lytic replication. In the middle and late stages,
activated p53 is subjected to BZLF1-dependent degradation to
maintain an S-phase-like environment for efficient viral propaga-
tion (Figure 1B).
Several groups have reported that BZLF1 is transiently
expressed as an immediate-early gene following EBV primary
infection of resting B lymphocytes, although early and late lytic
gene expression is very low or undetectable [44,45,46]. A transient
BZLF1 expression at the primary infection may contribute to
establishing a latent infection, as speculated by Wen and
colleagues [44]. This could be driven by degradation of p53,
which blocks reprogramming of B lymphocyte proliferation.
Interestingly, p53 serves as a negative regulator for reprogram-
ming of somatic cells into induced pluripotent stem (iPS) cells
[47,48,49,50,51]. Thus, it is possible that the degradation of p53
by BZLF1 protein-associated ECS ubiquitin ligases contributes to
the efficient transformation of B lymphocytes.
Regulation of CDK Inhibitors during Lytic
Replication
The large body of evidence implicating Cullin-based E3
ubiquitin ligase in the regulation of diverse cellular processes
[52,53] provides us with new insights into their significance as
potential targets of viruses manipulating the host cellular system.
Post-translational modifications, especially phosphorylation and
ubiquitination, play a crucial role in cell-cycle progression.
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and G2-M transitions. Ubiquitination and its mediated proteolysis
are commonly facilitated to maintain threshold levels of cell-cycle
regulators. Two distinct classes of E3 ubiquitin ligase regulate cell-
cycle progression [52], possessing an adaptor protein to determine
substrate specificity [54,55,56]. E3 ligase activity of the anaphase-
promoting complex is required for the G2-M transition [57]. The
SCF (Skp1-Cul1-F-box protein) family of E3 ligase promotes
ubiquitination of phosphorylated substrates and typically targets
the mediators of G1-S transition [58]. For instance, ubiquitin-
mediated degradation of p27
Kip1 is regulated by the SCF
Skp2
complex only when p27
Kip1 is phosphorylated at Thr-187 by the
cyclin E-CDK2 complex, which induces S phase conditions
[59,60,61].
The EBV lytic program promotes specific cell cycle–associated
activity involved in progression from G1 to S phase, since virus-
productive replication occurs under S-phase-like circumstances
[18]. Similar to p53, CDK inhibitors are also regulated during
lytic replication, contributing to establishment of an S-phase-like
cellular environment with high-CDK activities [9,33]. c-Herpes-
viruses possess their own strategies to degrade p27
Kip1. For
example, Kaposi’s sarcoma-associated herpesvirus (KSHV)-
encoding cyclin (v-cyclin), a latent viral protein, forms a complex
with CDK6 to phosphorylate Thr-187 on p27
Kip1, leading to
down-regulation at the protein level [62,63]. Also, the viral cyclin
encoded by murine herpesvirus 68 preferentially associates with
CDK2 to phosphorylate Thr-187 on p27
Kip1 [64]. While EBV
does not encode any v-cyclin homologue in its genome, our recent
study revealed that the EBV protein kinase BGLF4 can
phosphorylate the Thr-187 residue of p27
Kip1, resulting in its
ubiquitination and degradation in an SCF
Skp2 ubiquitin ligase-
dependent manner [65] (Figure 2).
Manipulating the ubiquitin system by EBV involves two aspects
of its regulation: attachment of ubiquitin to a substrate and
removal from its substrate. As an EBV-encoding deubiquitinating
enzyme, BPLF1 deubiquitinates and reduces activity of EBV
Figure 2. Viral strategy to manipulate the cellular environment for its own genome replication. Induction of lytic replication elicits ATM-
dependent host cellular DNA damage responses, because newly synthesized viral DNA is sensed as ‘‘aberrant’’ [9]. The ATM signaling cascade, which
is modified by BGLF4 kinase-mediated c-H2AX induction [35], phosphorylates and activates downstream molecules including CHK2 and p53.
However, phosphorylated p53, which can transactivate p21
Cip1/Waf1 CDK inhibitor, associates with high affinity to BZLF1 protein–formed ECS
ubiquitin E3 ligase complex and then is ubiquitinated [37]. On the other hand, EBV protein kinase phosphorylates p27
Kip1 CDK inhibitor, thereby
leading to phosphorylation-mediated ubiquitination by the SCF complex [65]. Since these ubiquitinated proteins are degraded in a proteasome-
dependent manner, an S-phase-like environment with high CDK activity required for efficient viral replication is maintained during EBV lytic infection.
In parallel with this, replicative helicase activity of the MCM complex is inactivated by BGLF4-mediated phosphorylation of MCM4, causing the
inhibition of chromosomal DNA replication [34]. Phosphorylated RPA induced by the DNA damage response stimulates viral DNA replication through
homologous recombinational repair [40]. Taken together, EBV manipulates various signaling cascades and thereby achieves efficient viral replication.
doi:10.1371/journal.ppat.1001158.g002
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influences the function of the protein rather than targeting it for
proteasomal degradation. A recent paper documented that BPLF1
also act as a deneddylase [67]. Neddylation, which is a conjugation
of ubiquitin-like modifier NEDD8 to its substrate, is an important
mechanism for regulating Cullin-based E3 ubiquitin ligase [68].
EBV BPLF1 binds to Cullins and attenuates the activity of the
Cullin-RING ligases, resulting in accumulation of the licensing
factor Cdt1 and induction of DNA re-replication. Inhibition of
BPLF1 during the lytic infection prevents viral replication in the
cells that carries a recombinant EBV [67]. These findings support
the idea that manipulating ubiquitin system by virus promotes
viral productive replication. Furthermore, two lytic proteins
(BSLF1 and BXLF1) are found as deubiquitinases by a bioinfor-
matic search on the EBV genome [69], although their functions in
viral replication remain obscure. Further investigations are needed
to determine the exact role of deubiquitination in the context of
EBV lytic infection.
The level of another CDK inhibitor protein p21
Cip1/Waf1,o f
course, becomes low during lytic replication [36]. Although the
detailed mechanisms remain unknown, one reason is that p53 is
actively degraded during lytic infection and another is that
the SCF
Skp2 ubiquitin ligase complex directs p21
Cip1/Waf1 for
degradation through S-phase CDK-mediated phosphoryration
[70]. Recent study showed that KSHV-encoding microRNA,
miR-K1 represses expression of p21
Cip1/Waf in latent infection
[71]. As an additional mechanism, an EBV-encoding miRNA that
has yet to be discovered might regulate p21
Cip1/Waf1 for
maintaining S-phase-like conditions.
On the other hand, maintaining low levels of CDK inhibitors
results in accumulation of the hyperphosphorylated Rb protein
due to high S-phase CDK activities and causes accumulation of
active E2F-1 as lytic replication progresses [9]. E2F-1 in turn
activates the transcription of many proteins involved in cellular
DNA synthesis and cell-cycle progression [72], and probably
transcription of the EBV DNA polymerase gene as well [73]. The
available data suggest that E2F activity is required for lytic viral
DNA replication. Alternatively, the EBV immediate-early trans-
activator BZLF1 and BRLF1 proteins are reported to increase the
level of E2F-1 [74,75]. Furthermore, since activated ATM or
Chk2 phosphorylates and activates E2F-1 in response to DNA
damage [76,77], the DNA damage response induced by EBV lytic
replication could activate E2F-1. To achieve effective viral lytic
replication, EBV therefore possesses a variety of strategies to
maintain the S-phase-like cellular environment.
Beneficial Aspects of DNA Damage Signaling on
EBV DNA Replication
During EBV lytic replication, phosphorylated ATM and
Mre11/Rad50/Nbs1 (MRN) complexes are targeted to replica-
tion compartments in nuclei. Simultaneously, homologous recom-
binational repair (HRR) factors such as replication protein A
(RPA), Rad51, and Rad52, as well as MRN complex, are recruited
and loaded onto the newly synthesized viral genome in replication
compartments [40]. The 32 kDa subunit of RPA is extensively
phosphorylated at sites in accordance with these events [40].
Hyperphosphorylation of RPA32 causes a change in RPA
conformation, resulting in a switch from catalysis of DNA
replication to participation in DNA repair. RNAi knockdown of
RPA32 and Rad51 prevents viral DNA synthesis, suggesting that
homologous recombination and/or repair of the viral DNA
genome might occur, coupled with viral DNA replication to
facilitate viral genome synthesis (Figure 2). Thus, the host DNA
damage response induced by productive viral replication is
essential for efficient EBV lytic genomic replication.
Conclusions
Replication of DNA viruses in host cells triggers a variety of
cellular signaling cascades, including the DNA damage response.
Recent studies indicate that such cellular responses to viral
genomic replication paradoxically play a crucial role in EBV lytic
replication by establishing cellular conditions appropriate for
efficient viral replication. To achieve these conditions, EBV
manipulates host ubiquitin-proteasome systems, and thereby
cancels host antivirus signals. During lytic infection, the interaction
between BZLF1 protein and ECS E3 ligase complexes leads to
p53 degradation, and the SCF E3 complex recognizes and
ubiquitinates phosphorylated p27
Kip1 through viral protein kinase.
Therefore, by skipping the induction of checkpoint signaling and
apoptosis, virus-producing cells stay in a persistent S-phase-like
environment with high CDK activity.
Accession numbers
The Entrez Gene (http://www.ncbi.nlm.nih.gov/gene) acces-
sion numbers for genes and gene products discussed in this study
are as follows: p53 (7157), p21
Cip1/Waf1 (1026), p27
Kip1 (1027),
USP7 (7874), MDM2 (4193), E2F-1 (1869), ATM (472), Chk2
(11200), H2AX (3014), PARP (142), Skp2 (6502), Cdt1 (81620),
ubiquitin (7314), NEDD8 (4738), Rb (5925), Cyclin E (898),
Cyclin A (890), CDK2 (1017), CDK6 (1021), RPA32 (6118),
Rad51 (5888), Rad52 (5893), KSHV v-cyclin (4961471), and EBV
EBNA1 (3783709), BGLF4 (3783704) BPLF1 (3783726), BSLF1
(3783730), BXLF1 (3783741), and BZLF1 (3783744).
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